Compugen to Significantly Expand Immuno-Oncology Activitiesin 2014

Compugen

announced today that it is significantly increasing its Pipeline Program activities in the field of immuno-oncology. The primary purpose of the increase is to allow research and preclinical activities for a larger number of checkpoint target and product candidates for cancer immunotherapy to move forward in parallel. Additional objectives include the establishment of a biomarker discovery program for certain of the Company's checkpoint product candidates and the acceleration of experimental validation efforts for the recently disclosed antibody drug conjugate (ADC) target candidates for oncology. The significant increase in immuno-oncology activities during 2014 will impact both the target research and validation activities performed in Israel